Pacific Edge (ASX:PEB, NZE:PEB) said the draft 'Gapfill' prices for Cxbladder Triage Plus, a non-invasive genomic urine test, published by the US Centers for Medicare & Medicaid Services, proposed a draft price for the test of $1,018.44, according to Tuesday's Australian and New Zealand bourse filings.
The draft price sets the amount Pacific Edge will be reimbursed for all patients with Medicare and Medicare Advantage insurance in the US, subject to the Medicare Administrative Contractor, Novitas, providing coverage of the test.
It is currently listed as non-covered on Novitas' local coverage determination. The price is expected to take effect on Jan. 1, 2026.
Pacific Edge expects to submit a reconsideration request for coverage of Triage Plus as soon as the analytical validation and clinical validation studies have been published, per the filing.
Its shares soared 10% on market close on the New Zealand bourse.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.